This review integrates current knowledge on BAFF-dependent B-cell biology with mechanistic, pharmacokinetic, and clinical data to provide a comprehensive framework for understanding belimumab's effects in SLE and lupus nephritis (LN). This evidence concerns the gene TNFSF13B and lupus nephritis.